Stock Market News
Sinclair Pharma expects return to profit after revenues jump 20%
AIM-listed speciality pharmaceutical group Sinclair Pharma grew revenues by a fifth over the twelve months ended 31 December, as the effort put toward restructuring its European operations began to bear fruit.
Sales for Sinclair's trading year rose from £37.8m to £45.3m, or £43.2m on a constant currency basis, representing headline growth of 20%, as revenues of £25.2m over the second half bested the pace seen during the first six months of 2017 by 25%.
However, the group anticipated that it would only deliver a modest EBITDA profit for the year as a whole after continued investment to support the launch of its Silhouette InstaLift product in the US dragged its North American business unit to an adjusted EBITDA loss of nearly £1m.
Profitability throughout the year culminated in "notably strong" fourth quarter trading in Europe and Brazil, leading management to decide to take advantage of the strength in its ex-US business to reduce sales of Silhouette and Ellansé to distributors in the Middle East and South Korea, focusing instead on creating its own affiliates and joint-ventures in the aforementioned geographies.
Chris Spooner, chief executive officer, said, "Revenue growth in excess of 80% over the last two years will, as expected, return the Group to adjusted EBITDA profitability in 2017. Momentum in the business in the final quarter of 2017 was strong and whilst the re-order rate for US Silhouette Instalift is disappointing we are looking at a number of options to address this."
"The Board and I remain confident that 2018 will be another year of substantial revenue growth which will deliver further operating leverage," he added.
As of 1540 GMT, shares had advanced 6.98% to 23.00p.
Sales for Sinclair's trading year rose from £37.8m to £45.3m, or £43.2m on a constant currency basis, representing headline growth of 20%, as revenues of £25.2m over the second half bested the pace seen during the first six months of 2017 by 25%.
However, the group anticipated that it would only deliver a modest EBITDA profit for the year as a whole after continued investment to support the launch of its Silhouette InstaLift product in the US dragged its North American business unit to an adjusted EBITDA loss of nearly £1m.
Profitability throughout the year culminated in "notably strong" fourth quarter trading in Europe and Brazil, leading management to decide to take advantage of the strength in its ex-US business to reduce sales of Silhouette and Ellansé to distributors in the Middle East and South Korea, focusing instead on creating its own affiliates and joint-ventures in the aforementioned geographies.
Chris Spooner, chief executive officer, said, "Revenue growth in excess of 80% over the last two years will, as expected, return the Group to adjusted EBITDA profitability in 2017. Momentum in the business in the final quarter of 2017 was strong and whilst the re-order rate for US Silhouette Instalift is disappointing we are looking at a number of options to address this."
"The Board and I remain confident that 2018 will be another year of substantial revenue growth which will deliver further operating leverage," he added.
As of 1540 GMT, shares had advanced 6.98% to 23.00p.
Related share prices |
---|
Sinclair Pharma (SPH) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price